SCHEMBL31160643

SCHEMBL31160643

Oc1ccc([C@H]2Oc3cc(OCc4ccccc4)cc(OCc4ccccc4)c3C[C@H]2O)cc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.57
▸ BACE1 P56817 4/20 0.57
▸ HSD17B10 Q99714 4/20 0.57
▸ CYP3A4 P08684 4/20 0.57
▸ GAA P10253 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ MAPT P10636 3/20 0.57
▸ MEN1 O00255 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ MAPK1 P28482 3/20 0.57
▸ ALOX15 P16050 3/20 0.57
▸ SNCA P37840 3/20 0.57
▸ PKM P14618 2/20 0.57
▸ APEX1 P27695 2/20 0.57
▸ RECQL P46063 2/20 0.57
▸ ALPL P05186 2/20 0.57
▸ POLB P06746 2/20 0.57
▸ PTGS1 P23219 2/20 0.57
▸ PTGS2 P35354 2/20 0.57
▸ APP P05067 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31161060 1.00 KDM4E (0.57) KDM4EBACE1HSD17B10CYP3A4GAA
SCHEMBL13507916 0.92 KDM4E (0.65) KDM4EBACE1HSD17B10CYP3A4GAA
SCHEMBL14685988 0.90 CYP3A4 (0.55) KDM4EBACE1HSD17B10CYP3A4GAA
SCHEMBL3669026 0.89 CYP3A4 (0.50) KDM4EBACE1HSD17B10CYP3A4GAA
SCHEMBL9101384 0.89 CYP3A4 (0.50) KDM4EBACE1HSD17B10CYP3A4GAA
SCHEMBL24983638 0.89 CYP3A4 (0.50) KDM4EBACE1HSD17B10CYP3A4GAA
SCHEMBL13507688 0.89 CYP3A4 (0.50) KDM4EBACE1HSD17B10CYP3A4GAA
SCHEMBL13507373 0.89 CYP3A4 (0.50) KDM4EBACE1HSD17B10CYP3A4GAA
SCHEMBL13507904 0.89 CYP3A4 (0.50) KDM4EBACE1HSD17B10CYP3A4GAA
SCHEMBL4640426 0.89 CYP3A4 (0.50) KDM4EBACE1HSD17B10CYP3A4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698522-A1 METHODS FOR PREPARING (-)-EPICATECHIN Mars, Incorporated (US) 2026-02-25 — — EP claimed
US-20260042741-A1 METHODS FOR PREPARING (-)-EPICATECHIN MARS, INCORPORATED (US) 2026-02-12 — — US claimed
WO-2024220193-A1 METHODS FOR PREPARING (-)-EPICATECHIN MARS, INCORPORATED (US) 2024-10-24 — — WO claimed
EP-4698522-A1 METHODS FOR PREPARING (-)-EPICATECHIN Mars, Incorporated (US) 2026-02-25 — — EP disclosed
US-20260042741-A1 METHODS FOR PREPARING (-)-EPICATECHIN MARS, INCORPORATED (US) 2026-02-12 — — US disclosed
WO-2024220193-A1 METHODS FOR PREPARING (-)-EPICATECHIN MARS, INCORPORATED (US) 2024-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042741-A1 METHODS FOR PREPARING (-)-EPICATECHIN CYP2E1, CYP1A1, ADH1A KDM4E 418/4885BACE1 3406/4885HSD17B10 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback